Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective

  title={Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective},
  author={Crystal Jing Jing Yeo and Zachary Simmons},
  journal={Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration},
  pages={167 - 172}
  • C. Yeo, Z. Simmons
  • Published 15 January 2018
  • Psychology, Medicine
  • Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Abstract The recent approval of edaravone by the United States Food and Drug Administration has generated a mix of hope tempered by reality. The costs of the drug, both monetarily and with regard to intensity of treatment, are high. The benefits, while modest, will be viewed through a very different lens by individuals depending on their goals of care. By virtue of our training and experience, physicians are ideally suited to understand and explain new treatments to our patients. As healthcare… 
Integration of a palliative care specialist in an amyotrophic lateral sclerosis clinic: Observations from one center
Patients with complex goals of care may benefit from the input of a palliative care specialist, and unique integration models may help to facilitate care delivery.
Palliative care in motor neurone disease: where are we now?
The aim of palliative care is to enable patients, and their families, to maintain as good a quality of life as possible and helping to ensure a peaceful death.
Comparison of the United Kingdom and United States approaches to approval of new neuromuscular therapies
The main downsides to the UK approach are that cost‐effective medications are often available months later than in the US, and some medications remain unavailable, whereas they are available at cost‐ effective prices in the UK.
Gamisoyo-San Ameliorates Neuroinflammation in the Spinal Cord of hSOD1G93A Transgenic Mice
GSS inhibits the expression of proteins related to Toll-like receptor 4 signaling and oxidative stress, known to cause neuroinflammation, and regulates metabolism in the spinal cord of transgenic mice, suggesting that GSS could be used for improving the immune system and increasing the life quality of patients with ALS.
Minimizing the Diagnostic Delay in Amyotrophic Lateral Sclerosis: The Role of Nonneurologist Practitioners
The diagnostic delay of ALS appears to be proportionately very long, sometimes longer than that observed in previous studies (because it also included the total delay to diagnostic or treatment initiation); the rapid execution of useful additional tests by the first medical doctor, often GP (with the help of a neurologist), considerably reduces the diagnostic delay.
Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study
Evidence in support of the disease-modifying effects of EH301 for the treatment of ALS is provided, shown to significantly slow the progression of ALS relative to placebo, and even showed improvements in several key outcome measures compared with baseline.
NIV in amyotrophic lateral sclerosis: The ‘when’ and ‘how’ of the matter
Non‐invasive ventilation in ALS has been considerably improved as a result of application of all of these measures, avoiding the need for tracheostomy in the very great majority of cases.
Psychosoziale Versorgung bei Patienten mit Amyotropher Lateralsklerose: Ein narrativer Review
Dieser narrative Review soll einen breiten Überblick zur psychosozialen Belastung bei Patienten mit Amyotropher Lateralsklerose (ALS) und diesbezüglichen psychotherapeutischen Interventionen
Amiyotrofik Lateral Skleroz Tedavisinde Güncel Onaylanmış Hastalık Modifiye Edici Tedavi: Riluzol ve Edaravone
Motor noron hastaliginin prototipi olan Amiyotrofik lateral Skleroz (ALS) patogenezinin tam olarak anlasilamamis olmasi ve hastaligin yuz guldurucu bir tedavisinin olmamasi tani surecini hasta ve
Edaravone in the treatment of amyotrophic lateral sclerosis.


July 2017 ENCALS statement on edaravone
It was showed that edaravone may slow disease progression in ALS, but the disease-modifying effect was limited to a subgroup of ALS patients with distinct clinical characteristics, and for ALS patients without those characteristics there is currently no evidence for a therapeutic benefit of edarvone.
Is quality of life determined by expectations or experience?
It is argued that perceptions of health and its meaning vary between individuals and within an individual over time and a model of the relation between expectations and experience is proposed to illustrate problems in measuring quality of life.
Health literacy : a prescription to end confusion
Health Literacy: Prescription to End Confusion examines the body of knowledge that applies to the field of health literacy, and recommends actions to promote a health literate society.
Patient-Perceived Outcomes and Quality of Life in ALS
A variety of outcome measures are used in clinical practice and in research to assess patients with amyotrophic lateral sclerosis (ALS). However, there may be discordance between traditional outcome
Correlates of suffering in amyotrophic lateral sclerosis
Many patients with ALS suffer and their suffering is correlated to pain and hopelessness, and the correlates of poor quality of life were poor social support and increasing hopelessness.
A study comparing patients with amyotrophic lateral sclerosis and their caregivers on measures of quality of life, depression, and their attitudes toward treatment options
There was, however, no significant difference between patients and caregivers on scores of QOL and depression, and over one-half of both groups would consider percutaneous esophageal gastrostomy placement.
Quality of life in fatal disease: the flawed judgement of the social environment
It is suggested that caregivers and the general public significantly underestimate the quality of life (QoL) of ALS patients and a positive affective state can indeed be preserved in a progressive, fatal disease.
Quality of life in ALS is maintained as physical function declines
QOL in patients with ALS appears to be independent of physical function, which agrees with a previous cross-sectional study, and the ALS-specific health-related QOL score is primarily a measure ofPhysical function.
Disparities in perceptions of distress and burden in ALS patients and family caregivers
Caregivers can accurately report information about a patient’s physical function at the end of life, however, patients and caregivers each overestimated the psychosocial impact of the disease on the other.
Assessing decision-making capacity at end of life.
Clinicians working with terminally ill patients should frequently assess capacity as these individuals are called on to make important medical decisions, and comprehensive assessment will aid clinicians in their Responsibility to balance respect for patient autonomy with their responsibility to protect patients from harm resulting from impaired decisional capacity.